Results 171 to 180 of about 64,482 (277)

B-Vitamins in Epileptics [PDF]

, 1986
Arab, L., Berlit, Peter, Bonjour, Jean-Pierre, Krause, Klaus-Henning, Kynast, Gisela, Schmidt-Gayk, Heinrich, Somogyi, Johann C.   +6 more
core   +1 more source

Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1371-1381, May 2026.
The World Health Organization Model Essential Medicines List and African national essential medicines lists (EMLs) detail drugs intended to be consistently available within national health systems, thereby supporting clinicians and pharmacists in making evidence‐based treatment decisions.
Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Janine Scholefield, Collen Masimirembwa   +5 more
wiley   +1 more source

Leveraging developmental neurotoxicity data in zebrafish embryos through the use of artificial intelligence methods. [PDF]

Front Toxicol
Heusinkveld HJ, Hessel EVS, Zwart EP, Gremmer ER, Pennings JLA.   +4 more
europepmc   +1 more source

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1382-1390, May 2026.
Genetic variation has a significant impact on patients' response to medicines. Variations in important pharmacogenes have been evaluated in several studies and consequently led to international guidelines from clinical pharmacogenomics consortia. However, there are limited examples of these being implemented across the African continent despite the ...
Janine Scholefield, Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Collen Masimirembwa   +5 more
wiley   +1 more source

Evaluation of neurotoxicity of drugs from morphological and electrophysiological endpoints using human iPSC-derived neural cell models. [PDF]

Front Cell Infect Microbiol
Qu Z, Li S, Qiu J, Huo G, Liu Y, Zhang D, Yang Y, Geng X, Lin Z.   +8 more
europepmc   +1 more source

Should PNPO Deficiency Be Treated In Utero? Clinical Findings From Prenatal Pyridoxine Therapy

JIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Pyridox(am)ine‐5′‐phosphate oxidase (PNPO) deficiency is characterized by early‐onset epileptic encephalopathy refractory to standard antiseizure medications. It is caused by variants in the PNPO gene, resulting in deficient PNPO enzyme activity, which normally converts pyridoxine‐5′‐phosphate and pyridoxamine‐5′‐phosphate (two vitamers of ...
Chloé de Puyraimond, Samia Pichard, Muriel Girard, Julian Delanne, Laurence Faivre, Apolline Imbard, Amandine Baurand, Jean‐François Benoist, Philippa B. Mills, Peter T. Clayton, Manuel Schiff   +10 more
wiley   +1 more source

Navigating a Dual Hyperinflammatory State: Overlap of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) and Secondary Hemophagocytic Lymphohistiocytosis (HLH) in a Child. [PDF]

Cureus
Gupta A, Prasad B, Dhumale A, Rajkumar K, Bhar VS, Gupta S.   +5 more
europepmc   +1 more source

1 g/h magnesium sulfate maintenance for eclampsia prevention is enough

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 5, Page 771-777, May 2026.
Magnesium sulfate maintenance regimen of 1 g/h seems as effective as the 2 g/h regimen for the prevention of eclampsia, with decreased incidence of maternal side effects. Abstract We conducted two systematic reviews including only randomized controlled trials (RCTs) comparing magnesium sulfate vs placebo/no treatment, as well as 2 g/h vs 1 g/h ...
Alessandro Petrecca, Benedetta Bina, Tullio Ghi, Vincenzo Berghella   +3 more
wiley   +1 more source

Antiseizure Treatments and Liver Injury: Expect (and Prevent) the Unexpected. [PDF]

Epilepsy Curr
Bunch M, Klocke S, Woodrich N, Barritt AS, Eyal S.   +4 more
europepmc   +1 more source

A model‐based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs

British Journal of Pharmacology, Volume 183, Issue 10, Page 2482-2496, May 2026.
Background The activity of CYP2C9, an important drug metabolism enzyme, is subject to the impact of genetic polymorphism. The single nucleotide polymorphism *3 is significantly associated with the increased exposure of CYP2C9 substrates. In addition, metabolic enzyme inhibitors such as fluconazole may also increase the drug exposure of CYP2C9 ...
Shen Cheng, Darcy R. Flora, Mutaz M. Jaber, Allan E. Rettie, Richard C. Brundage, Timothy S. Tracy   +5 more
wiley   +1 more source